Moderna seeks FDA authorization for second COVID booster for all adults By Reuters

© Reuters. FILE PHOTO: A vial and Foreign exchange dealers with the lowest spreadssryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) -Moderna Inc on late Thursday sought emergency use authorization with U.S. health regulators for a second COVID-19 booster shot for all adults, as a surge in cases in some parts of the world fuels fears of another wave of the pandemic.

The company's request comes days after Pfizer Inc (NYSE:PFE) and its German partner BioNTech SE (NASDAQ:BNTX) filed an application with the U.S. Food and Drug Administration, seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older.

Moderna (NASDAQ:MRNA) said its request covered all adults over the age of 18 so that U.S. Centers for Disease Control and Prevention (CDC) and health care providers could determine the appropriate use of an additional booster dose of its vaccine, including "for those at higher risk of COVID-19 due to age or comorbidities."

Moderna, without specifically commenting on the effectiveness of a fourth shot, said its submission was partly based on data recently published in the United States and Israel following the emergence of the Omicron variant.

FDA did not immediately respond to a Reuters request for comment.

U.S. health officials, including top infectious disease expert Dr. Anthony Fauci, have raised the prospect of a fourth shot, especially for older people and to prepare for the possibility of another surge in cases.

U.S. Centers for Disease Control and Prevention data has said that vaccine efficacy wanes over time and that a third shot helps restore it, but it has not released comprehensive data based on age or health status to support the case.

The news was first reported by the New York Times.

Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!